Clinical characteristics of the dataset
| All patients | Responders | Non-responders | Hyperprogressors | P value (χ2) | ||
| Number of patients | 109 (100%) | 50 (45.87%) | 40 (36.70%) | 19 (17.43%) | – | |
| Gender | Female | 51 (46.79%) | 24 (48.00%) | 20 (50.00%) | 7 (36.84%) | 0.62 |
| Male | 58 (53.21%) | 26 (52.00%) | 20 (50.00%) | 12 (63.16%) | ||
| Smoking | Current | 18 (16.51%) | 6 (12.00%) | 7 (17.50%) | 5 (26.13%) | <0.001 |
| Former | 68 (62.38%) | 40 (80.00%) | 25 (62.50%) | 3 (15.79%) | ||
| Never | 23 (21.10%) | 4 (8.00%) | 8 (20.00%) | 11 (57.89%) | ||
| Stage at diagnosis | Stages I and II | 13 (11.93%) | 6 (12.00%) | 7 (17.50%) | 0 (0.00%) | 0.084 |
| Stage III | 14 (12.84%) | 8 (16.00%) | 6 (15.00%) | 0 (0.00%) | ||
| Stage IV | 82 (75.23%) | 36 (72.00%) | 27 (67.50%) | 19 (100.00%) | ||
| Histology | Adenocarcinoma | 71 (65.14%) | 37 (74.00%) | 23 (57.50%) | 12 (63.16%) | 0.38 |
| SCC | 27 (24.77%) | 8 (16.00%) | 13 (32.50%) | 6 (31.58%) | ||
| Other | 10 (9.17%) | 5 (10.00%) | 4 (10.00%) | 1 (5.26%) | ||
| EGFR mutation | Yes | 9 (8.26%) | 2 (4.00%) | 3 (7.50%) | 4 (21.05%) | 0.021 |
| No | 78 (71.56%) | 42 (84.00%) | 26 (65.00%) | 10 (52.63%) | ||
| Unknown | 22 (20.18%) | 6 (12.00%) | 11 (27.50%) | 5 (26.32%) | ||
| ICI agent | Nivolumab | 91 (83.49%) | 34 (68.00%) | 39 (97.50%) | 17 (89.47%) | 0.0046 |
| Pembrolizumab | 13 (11.93%) | 11 (22.00%) | 0 (0.00%) | 2 (10.53%) | ||
| Atezolizumab | 6 (5.50%) | 5 (10.00%) | 1 (2.50%) | 0 (0.00%) |
ICI, immune checkpoint inhibitor; SCC, squamous cell carcinoma.